← Leaderboards
Paul Limburg
Mayo Clinic Rochester
$5,310,518
Attributed
$5,310,518
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2014–23$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$5,310,518 · 1
By mechanism
N01$5,310,518 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsSafetyPlacebosParticipantBiologicalRandomizedDouble-Blind Placebo Controlled TrialPremalignantPrimary EndpointMaintenanceCountryArachidonic AcidsAsiaAmerican Cancer SocietyCancer EtiologyCurcuminEastern EuropeChemokineCessation Of LifeChemopreventive AgentAntioxidantsCancer BurdenDisability-Adjusted Life YearsBioflavonoid
Grant awards (21)
CORE INFRASTRUCTURE SUPPORT FOR THE CANCER PREVENTION AGENT DEVELOPMENT PROGRAM$158,652
N01 · FY2023 · CA · contact PI
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MERIVA (R) AS A CANDIDATE CHEMOPREVENTION AGENT FOR GASTRIC CARCINOGENESIS$11,000
N01 · FY2023 · CA · contact PI
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MERIVA (R) AS A CANDIDATE CHEMOPREVENTION AGENT FOR GASTRIC CARCINOGENESIS$73,976
N01 · FY2022 · CA · contact PI
CORE INFRASTRUCTURE SUPPORT FOR THE CANCER PREVENTION AGENT DEVELOPMENT PROGRAM$54,197
N01 · FY2022 · CA · contact PI
CORE INFRASTRUCTURE SUPPORT FOR THE CANCER PREVENTION AGENT DEVELOPMENT PROGRAM$512,594
N01 · FY2021 · CA · contact PI
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MERIVA (R) AS A CANDIDATE CHEMOPREVENTION AGENT FOR GASTRIC CARCINOGENESIS$41,160
N01 · FY2021 · CA · contact PI
CORE INFRASTRUCTURE SUPPORT FOR THE CANCER PREVENTION AGENT DEVELOPMENT PROGRAM$807,663
N01 · FY2020 · CA · contact PI
A PILOT STUDY OF MUC1 VACCINE IN CURRENT AND FORMER SMOKERS AT HIGH RISK FOR LUNG CANCER$15,640
N01 · FY2020 · CA · contact PI
CORE INFRASTRUCTURE SUPPORT FOR THE CANCER PREVENTION AGENT DEVELOPMENT PROGRAM$1,032,129
N01 · FY2019 · CA · contact PI
A PILOT STUDY OF MUC1 VACCINE IN CURRENT AND FORMER SMOKERS AT HIGH RISK FOR LUNG CANCER$336,870
N01 · FY2019 · CA · contact PI
PHASE I DOUBLE- BLIND, PLACEBO-CONTROLLED TRIAL OF 0.3MG LINACLOTIDE DELAYED-RELEASE (DR1) TO DEMONSTRATE COLORECTAL BIOACTIVITY IN HEALTHY VOLUNTEERS$206,377
N01 · FY2019 · CA · contact PI
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MERIVA (R) AS A CANDIDATE CHEMOPREVENTION AGENT FOR GASTRIC CARCINOGENESIS$26,790
N01 · FY2019 · CA · contact PI
MUC1 Vaccine in Patients with Newly Diagnosed Advanced Adenomas$20,841
N01 · FY2018 · CA · contact PI
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MERIVA (R) AS A CANDIDATE CHEMOPREVENTION AGENT FOR GASTRIC CARCINOGENESIS$13,250
N01 · FY2018 · CA · contact PI
IGF::OT::IGF A PILOT STUDY OF MUC1 VACCINE IN CURRENT AND FORMER SMOKERS AT HIGH RISK FOR LUNG CANCER$390,096
N01 · FY2017 · CA · contact PI
IGF::OT::IGF PHASE I DOUBLE- BLIND, PLACEBO-CONTROLLED TRIAL OF 0.3MG LINACLOTIDE DELAYED-RELEASE (DR1) TO DEMONSTRATE COLORECTAL BIOACTIVITY IN HEALTHY VOLUNTEERS$243,804
N01 · FY2017 · CA · contact PI
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MERIVA (R) AS A CANDIDATE CHEMOPREVENTION AGENT FOR GASTRIC CARCINOGENESIS$24,042
N01 · FY2017 · CA · contact PI
IGF::OT::IGF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MERIVA (R) AS A CANDIDATE CHEMOPREVENTION AGENT FOR GASTRIC CARCINOGENESIS$538,137
N01 · FY2016 · CA · contact PI
IGF::OT::IGF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MUC1 VACCINE IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED ADENOMA$76,306
N01 · FY2016 · CA · contact PI
MUC1 Vaccine in Patients with Newly Diagnosed Advanced Adenomas$3,040
N01 · FY2016 · CA · contact PI
Contract HHSN261201200042I, 09/24/2012 - 09/23/2017Cancer Prevention Agent Development Program: Early Phase Clinical ResearchTask Order HHSN26100008, 09/24/2014 - 09/23/2015Core Infrastructure$723,954
N01 · FY2014 · CA · contact PI